The Alternative Splicing Mutation Database: a hub for investigations of alternative splicing using mutational evidence by Bechtel, Jason M et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Research Notes
Open Access Data Note
The Alternative Splicing Mutation Database: a hub for 
investigations of alternative splicing using mutational evidence
Jason M Bechtel1, Preeti Rajesh2,3, Irina Ilikchyan4, Ying Deng5, 
Pankaj K Mishra2, Qi Wang5, Xiaochun Wu2, Kirill A Afonin4, 
William E Grose2, Ye Wang4, Sadik Khuder1,6 and Alexei Fedorov*1,6
Address: 1Program in Bioinformatics and Proteomics/Genomics, University of Toledo Health Science Campus, Toledo, Ohio 43614, USA, 2Dept. 
of Medical Microbiology and Immunology, University of Toledo Health Science Campus, Toledo, Ohio 43614, USA, 3Dept. of Basic 
Pharmaceutical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina 29208, USA, 4Department 
of Biological Sciences, Bowling Green State University, Bowling Green, Ohio 43403, USA, 5College of Engineering, University of Toledo, Toledo, 
Ohio 43606, USA and 6Dept. of Medicine, University of Toledo Health Science Campus, Toledo, Ohio 43614, USA
Email: Jason M Bechtel - jason.bechtel@utoledo.edu; Preeti Rajesh - Preeti.Rajesh@utoledo.edu; Irina Ilikchyan - iirina@bgnet.bgsu.edu; 
Ying Deng - ydeng@utnet.utoledo.edu; Pankaj K Mishra - Pankaj.Mishra@utoledo.edu; Qi Wang - wangqi_19@yahoo.com; 
Xiaochun Wu - xiaochun.wu@utoledo.edu; Kirill A Afonin - afonink@bgnet.bgsu.edu; William E Grose - William.Grose@utoledo.edu; 
Ye Wang - yew@bgnet.bgsu.edu; Sadik Khuder - sadik.khuder@utoledo.edu; Alexei Fedorov* - alexei.fedorov@utoledo.edu
* Corresponding author    
Abstract
Background: Some mutations in the internal regions of exons occur within splicing enhancers and
silencers, influencing the pattern of alternative splicing in the corresponding genes. To understand
how these sequence changes affect splicing, we created a database of these mutations.
Findings: The Alternative Splicing Mutation Database (ASMD) serves as a repository for all exonic
mutations not associated with splicing junctions that measurably change the pattern of alternative
splicing. In this initial published release (version 1.2), only human sequences are present, but the
ASMD will grow to include other organisms, (see Availability and requirements section for the
ASMD web address).
This relational database allows users to investigate connections between mutations and features of
the surrounding sequences, including flanking sequences, RNA secondary structures and strengths
of splice junctions. Splicing effects of the mutations are quantified by the relative presence of
alternative mRNA isoforms with and without a given mutation. This measure is further categorized
by the accuracy of the experimental methods employed. The database currently contains 170
mutations in 66 exons, yet these numbers increase regularly.
We developed an algorithm to derive a table of oligonucleotide Splicing Potential (SP) values from
the ASMD dataset. We present the SP concept and tools in detail in our corresponding article.
Conclusion: The current data set demonstrates that mutations affecting splicing are located
throughout exons and might be enriched within local RNA secondary structures. Exons from the
ASMD have below average splicing junction strength scores, but the difference is small and is judged
not to be significant.
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Background
About 50% of mammalian genes exhibit alternative splic-
ing (AS) – the production of multiple mRNA isoforms
from the same gene, often in a tissue- or development
stage-specific manner. In humans, the number of different
types of expressed mRNA appears to be two to three times
higher than the total number of genes [1,2]. The regula-
tion of alternative splicing is a very intricate process which
involves the interaction of dozens of spliceosomal pro-
teins with a great variety of short sequence motifs inside
exons and introns. These regulatory motifs are known as
exonic splicing enhancers (ESEs), exonic splicing silencers
(ESSs), intronic splicing enhancers (ISEs), and intronic
splicing silencers (ISSs) [1,3]. Pre-mRNA secondary struc-
tures are also important players in the regulation of alter-
native splicing (see review [4]).
Significant progress in understanding AS has been
achieved in experimental research that characterized a
number of splicing enhancers and silencers [5-9] and also
in several bioinformatics approaches for computational
inference of ESEs and ESSs [10-18]. Despite this progress,
one cannot predict a tendency to alternative splicing from
genomic data. A set of mutations known to be associated
with alternative splicing effects (reviewed by [19,9]) pro-
vides valuable raw material for a broad range of studies
aiming to elucidate mechanisms of spliceosomal regula-
tion.
In order to advance this area of research, we have created
the Alternative Splicing Mutation Database (ASMD) – a
collection of human exon sequences with short (1–6
nucleotides) internal mutations that change the balance
of alternatively spliced mRNA isoforms or cause the
appearance of new mRNA isoforms. The ASMD includes
only those mutations that change exonic enhancers and
silencers and does not encompass those that change splice
sites (deletion of existing splice junctions or creation of
novel junctions). The ASMD is manually curated such that
each entry is meticulously verified with published litera-
ture describing the influence of the mutation on alterna-
tive splicing. This information has been converted into a
novel parameter, termed "Splicing Effect" or SE value. The
SE value lies within a range of [-1, +1] and reflects the
effect of a mutation on an observed change in the pattern
of alternative splicing. In the case of exon skipping, for
example, SE = -1 means that a mutation causes 100% skip-
ping of the constitutive wild-type exon. The database also
contains an evaluation of the accuracy of the experimental
techniques underlying the SE value for each mutation.
The ASMD web site allows for the display of an array of
information on every database entry, including splice site
strength scores and putative RNA secondary structures.
There already exist many AS-related databases dating back
to 1999. They are all important for their contributions to
the understanding of alternative splicing. Nevertheless,
the ASMD's focus on mutations sets it apart from each of
these efforts. Analyzing a high-quality, curated database of
mutations could conceivably lead to the identification of
novel mediators of splicing and give a unique evaluation
of the strength of splicing enhancers and silencers.
Construction and content
The Alternative Splicing Mutation Database (ASMD) ver-
sion 1 uses a relational database (MySQL) to accurately
represent the relationships between the core entities:
genes, mutations, and splicing effects. In addition, the
database incorporates annotation information in the
form of putative local RNA secondary structures, splice
sites and their consensus value and log-odds scores.
Finally, references, notes, and depositor information has
been included in the database to facilitate long-term
growth and collaboration.
All wild-type sequences are derived from the human
Exon-Intron Database, most from version 35p1, some
from version 36p1 [20,21]. Both wild-type and mutant
exon sequences for each mutation are stored in the
sequences table. Mutant sequences are generated by the
incorporation of published mutations into the wild-type
sequence. All sequences are then properly annotated in
the sequence feature table. Splice site scores are calculated
using both the consensus value and log-odds methods, as
described in Zhang et al. 2005 [10]. Local RNA secondary
structures are predicted using the RNALfold utility from
the Vienna RNA package, version 1.6.1 [22], with default
parameters and a window size of 30 nucleotides. Only
structures with a minimum free energy (mfe) of -10.0
kcal/mol or lower were loaded into the database.
Explanations of "Splicing Effect" (SE) values, determina-
tion of SE accuracy levels, and other parameters are pro-
vided in the glossary, which is accessible from the home
page.
Utility
ASMD dataset and browsing features
The ASMD web site consists of three main sections: a
home page, a search page, and a public depositions area.
The home page is the starting point and provides connec-
tions to all parts of the site. The search page is used for
locating mutations and splicing effects in the database. It
contains the complete search form at the bottom of the
page. Figure 1 shows four entries of the ASMD and Figure
2 shows the search form. Views of mutations as well as
sequences of genes and exons are accessible from this
page. Figure 3 shows part of the detailed mutation view,
which is accessible through the ASMD identifier. The pub-BMC Research Notes 2008, 1:3 http://www.biomedcentral.com/1756-0500/1/3
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lic depositions area contains instructions and forms for
the submission of mutations, published references, and
notes.
The ASMD sequence data is available in FASTA format
from a link on the home page. The informational lines in
the file contain characteristics of the gene, the mutation,
and the associated splicing effect(s) while the sequence
contains the wild-type exon in which the mutation occurs.
An explanation of the FASTA-formatted data is available
on the web site.
ASMD usage
We expect researchers interested in understanding alterna-
tive splicing (AS) will use ASMD in their investigations in
two complementary ways. By searching in ASMD for
genes, exons, and mutations of interest, it is hoped that
researchers may be able to link observed AS isoforms with
particular mutations and their correlated sequence fea-
tures, such as putative RNA secondary structures. And
depositing new mutations and their splicing effects into
ASMD, we foresee researchers interactively improving the
power and utility of this resource.
ASMD search results example Figure 1
ASMD search results example. This screen capture shows the first four entries from the default search (i.e. no restric-
tions). The fields in blue are links to further views of the data. The colored boxes next to the SE values code the accuracy of 
the data. Explanations for accuracy levels and for fields marked with the blue and white question mark icon are available on the 
glossary page on the web site.
ASMD search form Figure 2
ASMD search form. This screen capture shows the complete search form. Note that the numbers in parentheses next to 
each category represent a count of the splicing effects, not the mutations in that category.BMC Research Notes 2008, 1:3 http://www.biomedcentral.com/1756-0500/1/3
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Because ASMD fundamentally differs from other AS data-
bases in its focus on the effects of mutations, it functions
differently from other existing databases. Instead of
receiving an exhaustive list of observed alternative splicing
events for a gene or exon of interest, a researcher using
ASMD can expect to find a curated list of small mutations
that are correlated with alternative splicing effects, as doc-
umented in the literature. This will enable researchers to
craft experiments accordingly, to either avoid duplication
of effort or to further understanding of AS regulation,
both at specific loci and in general.
Future development
The main task for the ASMD is to expand its dataset to
cover all known mutations that affect splicing. The proc-
ess of culling examples from the literature continues and
new mutations are being added monthly. We are in the
process of updating our sequences to build 36.1 of the
human genome. Updates for tools and calculations will
be performed every six months as the database grows.
Currently, entries are limited to mutations inside human
exons. In future releases we wish to expand the domain to
include mutations inside introns and in other mamma-
lian species. Accordingly, we plan to expand our analysis
of RNA secondary structures into all parts of pre-mRNA
including introns and splicing junctions. Once a sufficient
variety of exonic and intronic mutations is obtained for a
given gene, a new display will be added to capture the
effects of multiple mutations on alternative splicing.
Where data exists, this display could also capture the syn-
ergistic effects of multiple mutations, a phenomenon
already documented in the literature [23].
ASMD data analysis
ASMD version 1.1 data demonstrate that mutations affect-
ing splicing are located throughout exons and are not
restricted to the ends near splice junctions (see Fig. 4). An
analysis of 34 unique exons in the database shows that
their splice site strengths have median scores slightly below
those of all human exons (see Fig. 5). The difference is
small, however, compared to the standard deviation and
is judged not to be significant.
ASMD version 1.1 data suggest that mutations affecting
splicing are somewhat enriched within local RNA second-
ASMD sequence comparison display Figure 3
ASMD sequence comparison display. This screen capture shows the sequence comparison display from the detailed 
mutation view (obtained by clicking on the ASMD ID in the search results). The mutation position is highlighted in red. The 
splice site strength scores are shown in blue along with the flanking intronic sequences. The putative local RNA secondary 
structure ("fold") is shown along with its minimum free energy (mfe) value. Note how the mutation disrupts the base-pairing in 
the stem of the fold, substantially reducing the strength of the fold.BMC Research Notes 2008, 1:3 http://www.biomedcentral.com/1756-0500/1/3
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ary structures (LRSS). Further, those mutations within
LRSS may specifically avoid loops and may have a special
preference for "dangling ends" (bases adjacent to helices
in free ends and multi-loops).
We first observed that there are no strong LRSS in wild-
type exons with mutations conferring a positive splicing
effect (i.e. decreased skipping). The only putative LRSS in
this subset of exons has a calculated minimum free energy
(mfe) of -9.0 kcal/mol. None of the splice-affecting muta-
tions in that exon (exon #10 of the CFTR gene) coincide
with this putative secondary structure.
The ASMD version 1.1 dataset contains 91 mutations con-
ferring a negative splicing effect (i.e. increased skipping).
There is a greater prevalence of putative LRSS in the exons
carrying these mutations. 11% of the bases in these exon
sequences are within putative LRSS. The number of
observed mutations within LRSS compared to random
expectation represents an average enrichment of 21% for
ten different combinations of folding parameters. The
mutations that occur within putative LRSS of -10 kcal/mol
or stronger are ASMD IDs 12, 25, 46, 47, 49, 52, 60, 73,
112, and 116.
We also examined the presence of splice-affecting muta-
tions in stems and loops, where stem positions were fur-
ther broken down into base-pairings, bulges, and
dangling ends. Over the same set of parameter combina-
tions, the average percentage of mutations within loops,
base-pairings, bulges, and dangling ends is 5, 40, 35, and
20%, respectively.
We judge the current data to indicate a slight trend toward
splice-affecting mutations occurring within the stems of
local RNA secondary structures, specifically at the "dan-
gling ends." However, subsequent Monte Carlo simula-
tions with the appropriate statistical tests (Chi-squared or
Fisher exact) revealed none of these trends to be statisti-
cally significant (α = 0.1) with the current data. Statistical
evaluation of a larger data set should be performed to con-
firm or reject these hypotheses.
Conclusion
The ASMD represents a collection of small internal exonic
mutations, not associated with splicing junctions, that
change the pattern of alternative splicing. The ASMD web
Distribution of the relative position of mutations within  exons Figure 4
Distribution of the relative position of mutations 
within exons. This histogram shows a generally even distri-
bution of mutation positions. The x-axis represents the rela-
tive position of each mutation within its exon, calculated as 
percentage of exon length. The lone spike around the 80–
90% position is an abundance of mutations from the experi-
mental mutagenesis data on exon #10 of the CFTR gene.
Splice site strength scores for wild-type ASMD exons vs. "all"  human exons Figure 5
Splice site strength scores for wild-type ASMD exons 
vs. "all" human exons. These density curves (smooth-line 
histograms) represent the relative strength of splice sites as 
determined by the consensus value (CV) method. Donor and 
acceptor sites are considered separately. The vertical dashed 
lines indicate the median values. The sample of 193,995 
human splice sites was obtained from the Exon-Intron Data-
base's dEID file, version hs35p1, and was confined to the 
purged sample of 11,316 non-redundant human genes 
referred to in the Methods section.BMC Research Notes 2008, 1:3 http://www.biomedcentral.com/1756-0500/1/3
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site allows a user to explore the connections between
mutations and features of their surrounding sequences,
including putative RNA secondary structures and
strengths of splice junctions. As the database grows, so too
will the predictive power of associated tools and our
understanding of the mechanisms regulating alternative
splicing. By creating the ASMD public deposition area, we
encourage the scientific community to participate in the
development of the database.
Methods
All calculations were performed using the ASMD dataset
version 1.1, which contained 119 mutations in 37 exons.
It is implemented using MySQL and PHP on GNU/Linux.
A set of 20,433 sequences of human intron-containing
protein coding genes from the Exon-Intron Database
[20,21] was purged of all homologs (≥50% protein iden-
tity) and of genes with multiple repetitive domains (more
than 4 repeats of the same 5-aa fragment) to obtain a
reduced set of 11,316 human genes. This sample of non-
redundant human genes is available from our web page
http://hsc.utoledo.edu/depts/bioinfo/asmd/ as file
"HS35.1.purge3.dEID".
Availability and requirements
Project name: The Alternative Splicing Mutation Data-
base
ASMD project home page: http://mco321125.meduo
hio.edu/~jbechtel/asmd/
Operating system(s): Platform-independent
Programming Language: PHP
Other requirements: a modern web browser (with CSS
and JavaScript support)
License: GNU GPL v3
Restrictions to use by non-academics: None (not appli-
cable under GPL)
List of abbreviations
AS: Alternative splicing; ASMD: The Alternative Splicing
Mutation Database; ESE: Exonic splicing enhancer; ESS:
Exonic splicing silencer; ISE: Intronic splicing enhancer;
ISS: Intronic splicing silencer; LRSS: Local RNA secondary
structure; SE: Splicing effect.
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